Paul Stang, PhD
Vice President, Global R&D Epidemiology
Janssen Research and Development
Paul Stang, PhD is the Vice-President of Global Epidemiology at Janssen Research and Development, leading a group of over 30 researchers who support observational research across Johnson & Johnson. Prior to joining J&J, Dr. Stang was a Vice-President at Cerner Corporation, which he joined after co-founding and serving as the Chief Scientific Officer of Galt Associates, a health care consulting and informatics start-up that was purchased by Cerner. He has worked as a college professor, and has held leadership positions of increasing responsibility in outcomes and epidemiology groups at Glaxo and SmithKline Beecham.
Dr. Stang leads the visualization and communications working group for OHDSI. Previously, he served as a research investigator for the Observational Medical Outcomes Partnership (OMOP), a public-private partnership whose aim is to design a series of investigations to objectively assess the performance, value and impact of observational data in monitoring the safety and benefit of medications. He has published widely in epidemiology, health outcomes, productivity, and communications, and he continues to serve as a reviewer for a number of journals and is a member of a number of research consortia, governance and scientific advisory boards.
Dr. Stang received his BA from University of North Carolina at Chapel Hill in Embryology and Genetics, Physician Assistant certification from the Bowman Gray School of Medicine, MS in Health Sciences Research from SUNY-Stony Brook, and PhD in Public Health-Epidemiology from the University of North Carolina at Chapel Hill. He was elected a Fellow in 2004 to the International Society for Pharmacoepidemiology and still retains adjunct faculty appointments at several institutions.
Madigan D, Stang PE, Berlin JA, et al. A Systematic Statistical Approach to Evaluating Evidence from Observational Studies. Annual Review of Statistics and Its Application. 2014;1(1):11-39.
Stang P, Ryan P, Hartzema AG, et al. Development and Evaluation of Infrastructure and Analytic Methods for Systematic Drug Safety Surveillance: Lessons and Resources from the Observational Medical Outcomes Partnership. In: Elizabeth B. Andrews NM, editor. Mann’s Pharmacovigilance. Third ed: Wiley-Blackwell; 2014. p. 866.
Ryan PB, Madigan D, Stang PE, Schuemie MJ, Hripcsak G. Medication-wide association studies. CPT Pharmacometrics Syst Pharmacol. 2013 Sep 18;2:e76.(doi):10.1038/psp.2013.52.
Ryan PB, Stang PE, Overhage JM, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013 Oct;36(Suppl 1):S143-58. doi: 10.1007/s40264-013-0108-9.
Hartzema AG, Reich CG, Ryan PB, et al. Managing data quality for a drug safety surveillance system. Drug Saf. 2013 Oct;36(Suppl 1):S49-58. doi: 10.1007/s40264-013-0098-7.
Stang PE, Ryan PB, Overhage JM, Schuemie MJ, Hartzema AG, Welebob E. Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey. Drug Saf. 2013 Oct;36(Suppl 1):S15-25. doi: 10.1007/s40264-013-0103-1.
Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Desideratum for evidence based epidemiology. Drug Saf. 2013 Oct;36(Suppl 1):S5-14. doi: 0.1007/s40264-013-0102-2.
Katz AJ, Ryan PB, Racoosin JA, Stang PE. Assessment of case definitions for identifying acute liver injury in large observational databases. Drug Saf. 2013 Aug;36(8):651-61. doi: 10.1007/s40264-013-0060-8.
Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013 Aug 15;178(4):645-51. doi: 10.1093/aje/kwt010. Epub 2013 May 5.
Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Response to comment on ’empirical assessment of methods for risk identification in healthcare data’. Stat Med. 2013 Mar 15;32(6):1075-7. doi: 10.02/sim.5725.
Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012 Dec 30;31(30):4401-15. doi: 10.1002/sim.5620. Epub 2012 Sep 27.
Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012 Aug;45(4):689-96. doi: 10.1016/j.jbi.2012.05.002. Epub Jun 7.
Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60. doi: 10.1136/amiajnl-2011-000376. Epub 2011 Oct 28.
Stang PE, Ryan PB, Dusetzina SB, et al. Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature. Health Outcomes Research in Medicine. 2012 2//;3(1):e37-e44.
Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010 Nov 2;153(9):600-6. doi: 10.7326/0003-4819-153-9-201011020-00010.
Ryan P, Welebob E, Hartzema A, Stang P, Overhage JM. Surveying US Observational Data Sources and Characteristics for Drug Safety Needs. Pharm Med. 2010 2010/08/01;24(4):231-8.
Iribarren C, Round AD, Peng JA, Lu M, Zaroff JG, Holve TJ, et al. Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study. Pharmacoepidemiol Drug Saf. 2013; doi: 10.1002/pds.3479.
Walker AM, Patrick AR, Lauer MS, Hornbrook MC, Marin MG, Platt R, Roger VL, Stang P, Schneeweiss S. A tool for assessing the feasibility of comparative effectiveness research. Comparative Effectiveness Research 2013; 3 (1): 11-20. DOI: http://dx.doi.org/10.2147/CERS40357
Merikangas KR, Ames M, Cui L, Stang PE, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry 2007; 64(10):1180-8.
Kessler RC, Stang PE (eds): Health and Work Productivity: Making the Business Case for Quality Healthcare. Chicago: University of Chicago Press, 2006.
Stang PE, Carson, AP, Rose KM, Mo J, Ephross SA, Shahar E, Szklo M. Headache, cerebrovascular symptoms, and stroke: The Atherosclerosis Risk in Communities Study. Neurology 2005; 64: 1573-1577.
Okun, S., D. McGraw, P. Stang, E. Larson. D. Goldmann, J. Kupersmith, R. Filart, R. M. Robertson, C. Grossmann, and M. D. Murray. 2013. Making the case for continuous learning from routinely collected data. Discussion Paper, Institute of Medicine, Washington, DC. http://www.iom.edu/makingthecase.
Gardner JS, Morris LA, Stang PE: Risk Perception and Risk Communication: Their Application to Drug Safety. (Chapter 22) in Pharmacoepidemiology and Therapeutic Risk Management. Harvey Whitney Books, Hartzema, Tilson, Chan (eds). 2008.
Dreyer N, Stang PE, Duggirala H, Samsa G: Registry Design (Chapter 3) in Gliklich RE, Dreyer NA (eds). Registries for Evaluating Patient Outcomes: A User’s Guide. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No. HHSA290200535I TO1.) AHRQ Publication No. 07-EHC001-1. Rockville, MD: Agency for Healthcare Research and Quality. April, 2007. Second edition, September 2010.